Protara Therapeutics

TARA54

Penny Stock

$2.51arrow_drop_down2.71%-$0.07

Penny Stock

TARA54

$2.51

arrow_drop_down2.71%-$0.07

Penny Stock

Performance History

Key Stats
Open	$2.57
Prev. Close	$2.58
EPS	-3.16
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$51.05M
PE Ratio	-

	LOW	HIGH
Day Range	2.44	2.62
52 Week Range	1.04	5.24

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.16

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Protara Therapeutics (TARA)

ArTara Therapeutics Inc (TARA) is a biopharmaceutical company focused on the development of treatments for rare and specialty diseases. The company's primary focus is on developing therapies that target unmet medical needs and have the potential to provide significant improvements in patient outcomes. ArTara Therapeutics is committed to delivering innovative and effective treatments to patients who need them most.

The stock price history of ArTara Therapeutics Inc (TARA) reflects the growth and potential of the company. Over the past few years, the stock has shown a steady increase in value, reflecting positive investor sentiment and the company's progress in developing its pipeline of therapeutic candidates.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Jesse Shefferman
Headquarters: New York
Employees: 25
Exchange: NASDAQ

Keep an eye on Protara Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Protara Therapeutics 's (TARA) price per share?

The current price per share for Protara Therapeutics (TARA) is $2.52. The stock has seen a price change of -$0.09 recently, indicating a -3.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Protara Therapeutics (TARA)?

For Protara Therapeutics (TARA), the 52-week high is $5.24, which is 108.35% from the current price. The 52-week low is $1.04, the current price is 141.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Protara Therapeutics (TARA) a growth stock?

Protara Therapeutics (TARA) has shown an average price growth of -4.94% over the past three years. It has received a score of 45 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Protara Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Protara Therapeutics (TARA) stock price performance year to date (YTD)?

As of the latest data, Protara Therapeutics (TARA) has a year-to-date price change of 19.76%. Over the past month, the stock has experienced a price change of 38.19%. Over the last three months, the change has been 27.02%. Over the past six months, the figure is -24.7%.

help

Is Protara Therapeutics (TARA) a profitable company?

Protara Therapeutics (TARA) has a net income of -$40.42M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$43.61M. Furthermore, the EBITDA is -$43.9M.

help

What is the market capitalization of Protara Therapeutics (TARA)?

Protara Therapeutics (TARA) has a market capitalization of $51.05M. The average daily trading volume is 2.53, indicating the stock's liquidity and investor engagement.

News

PROTARA THERAPEUTICS

FDA

FAST TRACK

INTRAVENOUS CHOLINE CHLORIDE

PARENTERAL SUPPORT

Oct 21, 2024

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

CHANGES IN COMPANY'S OWN SHARES

Jun 24, 2024

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday

Apr 12, 2024

Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now

MANAGEMENT STATEMENTS